In: NEOPLASMA, vol. 53, no. 4
P. Eriksson - D. Brattström - P. Hesselius - A. Larsson - S. Bergström - S. Ekman - H. Goike - G. Wagenius - O. Brodin - M. Bergqvist
Detaily:
Rok, strany: 2006, 285 - 290
O článku:
Non-small cell lung cancer (NSCLC) is derived from epithelial
cells and accounts for approximately 80% of all
lung cancers. Cytokeratins are specific for epithelial cells and
during malignant transformation the cytokeratin profile usually
remains constant. Angiogenesis is the formation of new blood
vessels out of the existing vascular bed. Vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF) are
potent circulating angiogenic factors. The aim of
the present study was to determine if increased levels of a new
cytokeratin assay (MonoTotal, which in comparison with
TPAcyk detects not only fragments of cytokeratins 8 and 18 but
also of cytokeratin 19) is correlated with circulating
angiogenic factors (VEGF and bFGF) and the secondary aim was to
investigate if increased levels of these circulating markers
are associated with survival.
In the present study, a total of 45 NSCLC patients (26 patients
stage IIIa and 19 patients stage IIIb) receiving only curatively
intended treatment for advanced NSCLC were included. These
patients donated a total of 291 serum samples during
follow-up which was investigated for the presence of MonoTotal,
VEGF and bFGF. MonoTotal was statistically significantly
correlated with bFGF (R=0.26, p=0.00049) and VEGF (R=0.26,
p=0.00007). From the time of histological diagnosis
until time of death, MonoTotal increased by 603 U/l (p<0.0001).
VEGF increased by 430 pg/ml (p=0.0004) whereas the corresponding
value for bFGF was 5.93 pg/ml (p=0.018).
MonoTotal, a newly developed commercial cytokeratin assay, seems
to be a potentially very interesting serum marker
that, in conjunction with other clinical data, might be used for
monitoring of patients with NSCLC.
Ako citovať:
ISO 690:
Eriksson, P., Brattström, D., Hesselius, P., Larsson, A., Bergström, S., Ekman, S., Goike, H., Wagenius, G., Brodin, O., Bergqvist, M. 2006. Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa—IIIb receiving curatively intended treatment. In NEOPLASMA, vol. 53, no.4, pp. 285-290. 0028-2685.
APA:
Eriksson, P., Brattström, D., Hesselius, P., Larsson, A., Bergström, S., Ekman, S., Goike, H., Wagenius, G., Brodin, O., Bergqvist, M. (2006). Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa—IIIb receiving curatively intended treatment. NEOPLASMA, 53(4), 285-290. 0028-2685.